{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T01:32:26Z","timestamp":1793323946446,"version":"4.5.0"},"reference-count":80,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:00:00Z","timestamp":1792195200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016148","name":"The University of Kansas Department of Pharmaceutical Chemistry","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016148","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.xphs.2026.104550","type":"journal-article","created":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T22:35:04Z","timestamp":1792276504000},"page":"104550","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of oxidative degradation on the bioavailability of subcutaneously administered adalimumab"],"prefix":"10.1016","volume":"115","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0098-5749","authenticated-orcid":false,"given":"Moustafa M.","family":"Abdelaziz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad","family":"Groer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7818-3146","authenticated-orcid":false,"given":"Yilue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Richards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8509-862X","authenticated-orcid":false,"given":"Maribel Espinoza","family":"Ballesteros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishini","family":"Ranatunga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5235-9677","authenticated-orcid":false,"given":"Huan","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2076-4107","authenticated-orcid":false,"given":"Xiaoqing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9196-4232","authenticated-orcid":false,"given":"Liang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4163-8794","authenticated-orcid":false,"given":"Thomas","family":"Dimke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Koepke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8773-0705","authenticated-orcid":false,"given":"Gerard","family":"Bruin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7451-3819","authenticated-orcid":false,"given":"Karoline","family":"Bechtold-Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5082-8672","authenticated-orcid":false,"given":"Christian","family":"Sch\u00f6neich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0288-6138","authenticated-orcid":false,"given":"M.","family":"Laird Forrest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.xphs.2026.104550_bib0081","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2025.2468845","article-title":"YAbS: The antibody society\u2019s antibody therapeutics database","volume":"17","author":"Rawat","year":"2025","journal-title":"mAbs"},{"issue":"1","key":"10.1016\/j.xphs.2026.104550_bib0002","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2191302","article-title":"Impact of IgG subclass on monoclonal antibody developability","volume":"15","author":"Cain","year":"2023","journal-title":"mAbs"},{"issue":"1","key":"10.1016\/j.xphs.2026.104550_bib0003","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2021.2014296","article-title":"Antibodies to watch in 2022","volume":"14","author":"Kaplon","year":"2022","journal-title":"mAbs"},{"issue":"3","key":"10.1016\/j.xphs.2026.104550_bib0004","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3390\/antib11030056","article-title":"Alternative routes of administration for therapeutic antibodies\u2013State of the art","volume":"11","author":"Pitiot","year":"2022","journal-title":"Antibodies"},{"issue":"15","key":"10.1016\/j.xphs.2026.104550_bib0005","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1016\/j.cell.2022.05.029","article-title":"Designing antibodies as therapeutics","volume":"185","author":"Carter","year":"2022","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.xphs.2026.104550_bib0006","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/cpt.3150","article-title":"Subcutaneous administration of monoclonal antibodies: pharmacology, delivery, immunogenicity, and learnings from applications to clinical development","volume":"115","author":"Davis","year":"2024","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.xphs.2026.104550_bib0007","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40259-018-0295-0","article-title":"Subcutaneous Administration of biotherapeutics: an overview of current challenges and opportunities","volume":"32","author":"Bittner","year":"2018","journal-title":"Biodrugs"},{"issue":"5","key":"10.1016\/j.xphs.2026.104550_bib0008","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/cpt.2823","article-title":"Development of therapeutic proteins for a new subcutaneous route of administration after the establishment of intravenous dosages: a systematic review","volume":"113","author":"Xu","year":"2023","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.xphs.2026.104550_bib0009","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1124\/dmd.114.059238","article-title":"Subcutaneous absorption of biotherapeutics: knowns and unknowns","volume":"42","author":"Richter","year":"2014","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.xphs.2026.104550_bib0010","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2020.1770028","article-title":"Influence of physiochemical properties on the subcutaneous absorption and bioavailability of monoclonal antibodies","volume":"12","author":"Datta-Mannan","year":"2020","journal-title":"mAbs"},{"issue":"3","key":"10.1016\/j.xphs.2026.104550_bib0011","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1208\/s12248-012-9367-0","article-title":"Mechanistic determinants of biotherapeutics absorption following SC administration","volume":"14","author":"Richter","year":"2012","journal-title":"AAPS J"},{"issue":"2","key":"10.1016\/j.xphs.2026.104550_bib0012","doi-asserted-by":"crossref","first-page":"243","DOI":"10.4161\/mabs.4.2.19387","article-title":"Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration","volume":"4","author":"Zheng","year":"2012","journal-title":"mAbs"},{"key":"10.1016\/j.xphs.2026.104550_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.108022","article-title":"Therapeutic antibodies \u2013 natural and pathological barriers and strategies to overcome them","volume":"233","author":"Al Ojaimi","year":"2022","journal-title":"Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.xphs.2026.104550_bib0014","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3390\/antib14010002","article-title":"Rat as a predictive model for Human clearance and bioavailability of monoclonal antibodies","volume":"14","author":"Robarge","year":"2024","journal-title":"Antibodies"},{"issue":"1","key":"10.1016\/j.xphs.2026.104550_bib0015","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.xphs.2019.08.005","article-title":"Proteolysis and oxidation of therapeutic proteins after intradermal or subcutaneous administration","volume":"109","author":"Varkhede","year":"2020","journal-title":"J Pharm Sci"},{"issue":"1","key":"10.1016\/j.xphs.2026.104550_bib0016","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s42003-018-0032-8","article-title":"Assessment of susceptible chemical modification sites of trastuzumab and endogenous human immunoglobulins at physiological conditions","volume":"1","author":"Schmid","year":"2018","journal-title":"Commun Biol"},{"issue":"Supplement","key":"10.1016\/j.xphs.2026.104550_bib0017","article-title":"Antioxidants and protein oxidation","volume":"33","author":"Griffiths","year":"2000","journal-title":"Free Radic Res"},{"key":"10.1016\/j.xphs.2026.104550_bib0018","series-title":"Defining Critical Quality Attributes for Monoclonal Antibody Therapeutic Products","author":"Reason","year":"2026"},{"issue":"3","key":"10.1016\/j.xphs.2026.104550_bib0019","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1002\/btpr.1548","article-title":"Quality attributes of recombinant therapeutic proteins: an assessment of impact on safety and efficacy as part of a quality by design development approach","volume":"28","author":"Eon-Duval","year":"2012","journal-title":"Biotechnol Prog"},{"issue":"2","key":"10.1016\/j.xphs.2026.104550_bib0020","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/jps.24136","article-title":"Effect of individual fc methionine oxidation on FcRn binding: met252 oxidation impairs FcRn binding more profoundly than Met428 oxidation","volume":"104","author":"Gao","year":"2015","journal-title":"J Pharm Sci"},{"issue":"11","key":"10.1016\/j.xphs.2026.104550_bib0021","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1016\/j.xphs.2018.07.024","article-title":"Effect of peroxide- versus alkoxyl-induced chemical oxidation on the structure, stability, aggregation, and function of a therapeutic monoclonal antibody","volume":"107","author":"Shah","year":"2018","journal-title":"J Pharm Sci"},{"issue":"11","key":"10.1016\/j.xphs.2026.104550_bib0022","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s11095-018-2467-5","article-title":"Mitigation of oxidation in therapeutic antibody formulations: a biochemical efficacy and safety evaluation of N-acetyl-tryptophan and L-methionine","volume":"35","author":"Dion","year":"2018","journal-title":"Pharm Res"},{"issue":"11","key":"10.1016\/j.xphs.2026.104550_bib0023","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1021\/js970143s","article-title":"Antioxidants for prevention of methionine oxidation in recombinant monoclonal antibody HER2","volume":"86","author":"Lam","year":"1997","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2026.104550_bib0024","article-title":"High-concentration L-methionine as a potent antioxidant for oxidation resistance and stability enhancement in high-concentration antibody therapeutics","volume":"10","author":"Wang","year":"2025","journal-title":"Int J Pharm X"},{"issue":"10","key":"10.1016\/j.xphs.2026.104550_bib0025","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1007\/s11095-011-0482-x","article-title":"Site-specific tryptophan oxidation induced by autocatalytic reaction of polysorbate 20 in protein formulation","volume":"28","author":"Lam","year":"2011","journal-title":"Pharm Res"},{"issue":"2","key":"10.1016\/j.xphs.2026.104550_bib0026","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11095-019-2689-1","article-title":"In vivo stability of therapeutic proteins","volume":"37","author":"Schuster","year":"2020","journal-title":"Pharm Res"},{"issue":"6","key":"10.1016\/j.xphs.2026.104550_bib0027","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.molimm.2010.12.009","article-title":"Impact of methionine oxidation in human IgG1 Fc on serum half-life of monoclonal antibodies","volume":"48","author":"Wang","year":"2011","journal-title":"Mol Immunol"},{"issue":"5","key":"10.1016\/j.xphs.2026.104550_bib0028","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.4161\/mabs.29601","article-title":"A novel approach to investigate the effect of methionine oxidation on pharmacokinetic properties of therapeutic antibodies","volume":"6","author":"Stracke","year":"2014","journal-title":"mAbs"},{"key":"10.1016\/j.xphs.2026.104550_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2026.115025","article-title":"Magnetic immunoprecipitation assay for the isolation of adalimumab and degradation products in preclinical biological samples","volume":"222","author":"Abdelaziz","year":"2026","journal-title":"Eur J Pharm Biopharm"},{"issue":"1","key":"10.1016\/j.xphs.2026.104550_bib0030","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1021\/acs.molpharmaceut.2c00840","article-title":"Visible light induces site-specific oxidative heavy chain fragmentation of a monoclonal antibody (IgG1) mediated by an iron(III)-containing histidine buffer","volume":"20","author":"Zhang","year":"2023","journal-title":"Mol Pharm"},{"issue":"W1","key":"10.1016\/j.xphs.2026.104550_bib0031","doi-asserted-by":"crossref","first-page":"W315","DOI":"10.1093\/nar\/gky497","article-title":"BeStSel: a web server for accurate protein secondary structure prediction and fold recognition from the circular dichroism spectra","volume":"46","author":"Micsonai","year":"2018","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"10.1016\/j.xphs.2026.104550_bib0032","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1016\/j.xphs.2019.01.015","article-title":"Impact of precipitation of antibody therapeutics after subcutaneous injection on pharmacokinetics and immunogenicity","volume":"108","author":"Kinderman","year":"2019","journal-title":"J Pharm Sci"},{"issue":"11","key":"10.1016\/j.xphs.2026.104550_bib0033","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1002\/pro.5560021106","article-title":"Resolution of the fluorescence equilibrium unfolding profile of trp aporepressor using single tryptophan mutants","volume":"2","author":"Royer","year":"1993","journal-title":"Protein Sci"},{"issue":"6","key":"10.1016\/j.xphs.2026.104550_bib0034","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1002\/pro.3170","article-title":"The fluorescence intensities ratio is not a reliable parameter for evaluation of protein unfolding transitions","volume":"26","author":"\u017dold\u00e1k","year":"2017","journal-title":"Protein Sci"},{"issue":"1","key":"10.1016\/j.xphs.2026.104550_bib0035","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/pro.3986","article-title":"In-depth interrogation of protein thermal unfolding data with MoltenProt","volume":"30","author":"Kotov","year":"2021","journal-title":"Protein Sci"},{"issue":"2","key":"10.1016\/j.xphs.2026.104550_bib0036","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.xphs.2020.10.039","article-title":"Tryptophan oxidation of a monoclonal antibody under diverse oxidative stress conditions: distinct oxidative pathways favor specific Tryptophan residues","volume":"110","author":"Jacobitz","year":"2021","journal-title":"J Pharm Sci"},{"issue":"18","key":"10.1016\/j.xphs.2026.104550_bib0037","doi-asserted-by":"crossref","first-page":"5088","DOI":"10.1021\/bi702238b","article-title":"Structure and stability changes of Human IgG1 Fc as a consequence of methionine oxidation","volume":"47","author":"Liu","year":"2008","journal-title":"Biochemistry"},{"issue":"24","key":"10.1016\/j.xphs.2026.104550_bib0038","doi-asserted-by":"crossref","first-page":"9199","DOI":"10.1021\/acs.analchem.3c00317","article-title":"Integration of NMR spectroscopy in an analytical workflow to evaluate the effects of oxidative stress on Abituzumab: beyond the fingerprint of mAbs","volume":"95","author":"Cerofolini","year":"2023","journal-title":"Anal Chem"},{"issue":"1","key":"10.1016\/j.xphs.2026.104550_bib0039","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/19420862.2016.1259046","article-title":"Demonstration of physicochemical and functional similarity between the proposed biosimilar adalimumab MSB11022 and Humira\u00ae","volume":"9","author":"Magnenat","year":"2016","journal-title":"mAbs"},{"issue":"24","key":"10.1016\/j.xphs.2026.104550_bib0040","doi-asserted-by":"crossref","first-page":"9199","DOI":"10.1021\/acs.analchem.3c00317","article-title":"Integration of NMR spectroscopy in an analytical workflow to evaluate the effects of oxidative stress on Abituzumab: beyond the fingerprint of mAbs","volume":"95","author":"Cerofolini","year":"2023","journal-title":"Anal Chem"},{"issue":"19","key":"10.1016\/j.xphs.2026.104550_bib0041","doi-asserted-by":"crossref","first-page":"9495","DOI":"10.1021\/acs.analchem.6b01958","article-title":"Understanding the impact of methionine oxidation on the biological functions of IgG1 antibodies using hydrogen\/deuterium exchange mass spectrometry","volume":"88","author":"Mo","year":"2016","journal-title":"Anal Chem"},{"key":"10.1016\/j.xphs.2026.104550_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.114401","article-title":"Predicting human subcutaneous bioavailability of monoclonal antibodies using an open flow microperfusion porcine model","volume":"389","author":"Schwagerle","year":"2026","journal-title":"J Control Release"},{"issue":"1","key":"10.1016\/j.xphs.2026.104550_bib0043","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2191302","article-title":"Impact of IgG subclass on monoclonal antibody developability","volume":"15","author":"Cain","year":"2023","journal-title":"mAbs"},{"issue":"5","key":"10.1016\/j.xphs.2026.104550_bib0044","doi-asserted-by":"crossref","first-page":"578","DOI":"10.4161\/mabs.21328","article-title":"Chromatographic analysis of the acidic and basic species of recombinant monoclonal antibodies","volume":"4","author":"Du","year":"2012","journal-title":"mAbs"},{"key":"10.1016\/j.xphs.2026.104550_bib0045","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1007\/s11095-026-04047-x","article-title":"Near UV and visible light-induced degradation of IgG2: photo-fenton reaction in citrate buffer","volume":"43","author":"Subelzu","year":"2026","journal-title":"Pharm Res"},{"issue":"4","key":"10.1016\/j.xphs.2026.104550_bib0046","doi-asserted-by":"crossref","first-page":"928","DOI":"10.4161\/mabs.28744","article-title":"Characterization and screening of IgG binding to the neonatal Fc receptor","volume":"6","author":"Neuber","year":"2014","journal-title":"mAbs"},{"issue":"10","key":"10.1016\/j.xphs.2026.104550_bib0047","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.4049\/jimmunol.1403014","article-title":"FcRn: the architect behind the immune and non-immune functions of IgG and albumin","volume":"194","author":"Pyzik","year":"2015","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.xphs.2026.104550_bib0048","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/s11095-013-1154-9","article-title":"In vivo fluorescence imaging of IgG1 aggregates after subcutaneous and intravenous injection in mice","volume":"31","author":"Filipe","year":"2014","journal-title":"Pharm Res"},{"issue":"6","key":"10.1016\/j.xphs.2026.104550_bib0049","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1021\/bc700482u","article-title":"Synthesis and evaluation of near-infrared (NIR) dye\u2212herceptin conjugates as photoacoustic computed tomography (PCT) probes for HER2 expression in breast cancer","volume":"19","author":"Bhattacharyya","year":"2008","journal-title":"Bioconjug Chem"},{"issue":"1","key":"10.1016\/j.xphs.2026.104550_bib0050","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/2191-219X-1-31","article-title":"Inert coupling of IRDye800CW to monoclonal antibodies for clinical optical imaging of tumor targets","volume":"1","author":"Cohen","year":"2011","journal-title":"EJNMMI Res"},{"issue":"11","key":"10.1016\/j.xphs.2026.104550_bib0051","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1124\/dmd.114.060319","article-title":"Evaluation of near infrared fluorescent labeling of monoclonal antibodies as a tool for tissue distribution","volume":"42","author":"Conner","year":"2014","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"10.1016\/j.xphs.2026.104550_bib0052","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1021\/acs.molpharmaceut.6b01091","article-title":"Tracking antibody distribution with near-infrared fluorescent dyes: impact of dye structure and degree of labeling on plasma clearance","volume":"14","author":"Cilliers","year":"2017","journal-title":"Mol Pharm"},{"key":"10.1016\/j.xphs.2026.104550_bib0053","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.cbpa.2021.01.009","article-title":"Not so innocent: impact of fluorophore chemistry on the in vivo properties of bioconjugates","volume":"63","author":"Usama","year":"2021","journal-title":"Curr Opin Chem Biol"},{"issue":"2","key":"10.1016\/j.xphs.2026.104550_bib0054","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ab.2010.03.036","article-title":"Fluorescent-labeled antibodies: balancing functionality and degree of labeling","volume":"402","author":"Vira","year":"2010","journal-title":"Anal Biochem"},{"issue":"2","key":"10.1016\/j.xphs.2026.104550_bib0055","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.xphs.2017.09.022","article-title":"The use of a 2,2\u2019-azobis (2-Amidinopropane) dihydrochloride stress model as an indicator of oxidation susceptibility for monoclonal antibodies","volume":"107","author":"Dion","year":"2018","journal-title":"J Pharm Sci"},{"issue":"2","key":"10.1016\/j.xphs.2026.104550_bib0056","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1021\/acs.chemrev.1c00256","article-title":"Alkoxy radicals see the light: new paradigms of photochemical synthesis","volume":"122","author":"Chang","year":"2022","journal-title":"Chem Rev"},{"key":"10.1016\/j.xphs.2026.104550_bib0057","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.freeradbiomed.2017.02.010","article-title":"Regulated methionine oxidation by monooxygenases","volume":"109","author":"Manta","year":"2017","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"10.1016\/j.xphs.2026.104550_bib0058","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jchromb.2006.11.050","article-title":"Comparison of methionine oxidation in thermal stability and chemically stressed samples of a fully human monoclonal antibody","volume":"850","author":"Chumsae","year":"2007","journal-title":"J Chromatogr B"},{"issue":"10","key":"10.1016\/j.xphs.2026.104550_bib0059","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1007\/s11095-011-0482-x","article-title":"Site-specific tryptophan oxidation induced by autocatalytic reaction of polysorbate 20 in protein formulation","volume":"28","author":"Lam","year":"2011","journal-title":"Pharm Res"},{"issue":"2","key":"10.1016\/j.xphs.2026.104550_bib0060","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.xphs.2020.10.039","article-title":"Tryptophan oxidation of a monoclonal antibody under diverse oxidative stress conditions: distinct oxidative pathways favor specific Tryptophan residues","volume":"110","author":"Jacobitz","year":"2021","journal-title":"J Pharm Sci"},{"issue":"3","key":"10.1016\/j.xphs.2026.104550_bib0061","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.101689","article-title":"Oxidation of specific tryptophan residues inhibits high-affinity binding of cocaine and its metabolites to a humanized anticocaine mAb","volume":"298","author":"Kirley","year":"2022","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.xphs.2026.104550_bib0062","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s11095-018-2545-8","article-title":"Impact of tryptophan oxidation in complementarity-determining regions of two monoclonal antibodies on structure-function characterized by hydrogen-deuterium exchange mass spectrometry and surface plasmon resonance","volume":"36","author":"Hageman","year":"2018","journal-title":"Pharm Res"},{"issue":"1","key":"10.1016\/j.xphs.2026.104550_bib0063","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.xphs.2019.10.051","article-title":"Unique impacts of methionine oxidation, tryptophan oxidation, and asparagine deamidation on antibody stability and aggregation","volume":"109","author":"Alam","year":"2020","journal-title":"J Pharm Sci"},{"issue":"8","key":"10.1016\/j.xphs.2026.104550_bib0064","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.3390\/ijms22083952","article-title":"Monoclonal antibody aggregation associated with free radical induced oxidation","volume":"22","author":"Zheng","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.xphs.2026.104550_bib0065","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s12104-024-10187-1","article-title":"Backbone and methyl side-chain resonance assignments of the Fab fragment of adalimumab","volume":"18","author":"Sarker","year":"2024","journal-title":"Biomol NMR Assign"},{"issue":"4","key":"10.1016\/j.xphs.2026.104550_bib0066","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1021\/mp400666b","article-title":"Examination of thermal unfolding and aggregation profiles of a series of developable therapeutic monoclonal antibodies","volume":"12","author":"Brader","year":"2015","journal-title":"Mol Pharm"},{"issue":"31","key":"10.1016\/j.xphs.2026.104550_bib0067","doi-asserted-by":"crossref","first-page":"5079","DOI":"10.1016\/j.chroma.2011.05.061","article-title":"Isolation and characterization of therapeutic antibody charge variants using cation exchange displacement chromatography","volume":"1218","author":"Zhang","year":"2011","journal-title":"J Chromatogr A"},{"issue":"4","key":"10.1016\/j.xphs.2026.104550_bib0068","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/S1097-2765(01)00230-1","article-title":"Crystal structure at 2.8 A of an FcRn\/heterodimeric Fc complex: mechanism of pH-dependent binding","volume":"7","author":"Martin","year":"2001","journal-title":"Mol Cell"},{"issue":"1","key":"10.1016\/j.xphs.2026.104550_bib0069","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0969-2126(98)00008-2","article-title":"Structural basis of pH-dependent antibody binding by the neonatal Fc receptor","volume":"6","author":"Vaughn","year":"1998","journal-title":"Structure"},{"issue":"2","key":"10.1016\/j.xphs.2026.104550_bib0070","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40259-021-00471-0","article-title":"Recent achievements and challenges in prolonging the serum half-lives of therapeutic IgG antibodies through fc engineering","volume":"35","author":"Ko","year":"2021","journal-title":"Biodrugs"},{"issue":"2","key":"10.1016\/j.xphs.2026.104550_bib0071","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/pro.45","article-title":"Methionine oxidation in human IgG2 Fc decreases binding affinities to protein A and FcRn","volume":"18","author":"Pan","year":"2009","journal-title":"Protein Sci"},{"issue":"18","key":"10.1016\/j.xphs.2026.104550_bib0072","doi-asserted-by":"crossref","first-page":"5088","DOI":"10.1021\/bi702238b","article-title":"Structure and stability changes of Human IgG1 Fc as a consequence of methionine oxidation","volume":"47","author":"Liu","year":"2008","journal-title":"Biochemistry"},{"issue":"2","key":"10.1016\/j.xphs.2026.104550_bib0073","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1080\/19420862.2015.1008353","article-title":"The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity","volume":"7","author":"Abdiche","year":"2015","journal-title":"mAbs"},{"issue":"12","key":"10.1016\/j.xphs.2026.104550_bib0074","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1039\/C3MB70231F","article-title":"Binding structures and energies of the human neonatal fc receptor with human Fc and its mutants by molecular modeling and dynamics simulations","volume":"9","author":"Huang","year":"2013","journal-title":"Mol Biosyst"},{"issue":"3","key":"10.1016\/j.xphs.2026.104550_bib0075","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s00296-006-0183-7","article-title":"Immunogenicity, efficacy and adverse events of adalimumab in RA patients","volume":"27","author":"Bender","year":"2007","journal-title":"Rheumatol Int"},{"issue":"14","key":"10.1016\/j.xphs.2026.104550_bib0076","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2011.406","article-title":"Development of antidrug antibodies against Adalimumab and association with disease activity and treatment failure during long-term follow-up","volume":"305","author":"Bartelds","year":"2011","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.xphs.2026.104550_bib0077","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/nrrheum.2013.4","article-title":"Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis","volume":"9","author":"van Schouwenburg","year":"2013","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.1016\/j.xphs.2026.104550_bib0078","doi-asserted-by":"crossref","first-page":"101","DOI":"10.4161\/mabs.4.1.18543","article-title":"Subcutaneous bioavailability of therapeutic antibodies as a function of FcRn binding affinity in mice","volume":"4","author":"Deng","year":"2012","journal-title":"mAbs"},{"issue":"16","key":"10.1016\/j.xphs.2026.104550_bib0079","doi-asserted-by":"crossref","first-page":"5607","DOI":"10.3390\/s21165607","article-title":"In vitro electrochemical detection of hydrogen peroxide in activated macrophages via a platinum microelectrode array","volume":"21","author":"Carriere","year":"2021","journal-title":"Sensors"},{"key":"10.1016\/j.xphs.2026.104550_bib0080","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.redox.2016.12.035","article-title":"Hydrogen peroxide as a central redox signaling molecule in physiological oxidative stress: oxidative eustress","volume":"11","author":"Sies","year":"2017","journal-title":"Redox Biol"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354926004004?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354926004004?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T01:04:09Z","timestamp":1793322249000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354926004004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":80,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S0022354926004004"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2026.104550","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of oxidative degradation on the bioavailability of subcutaneously administered adalimumab","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2026.104550","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Pharmacists Association\u00ae.","name":"copyright","label":"Copyright"}],"article-number":"104550"}}